Latest Healthcare News

Sigma Healthcare’s recent merger with Chemist Warehouse Group is delivering strong earnings growth, with Normalised EBIT rising 36% in the first half of FY25. Transaction costs remain significant but the combined group’s outlook appears robust.

Epsilon Healthcare reports ongoing operational challenges post-voluntary administration while unveiling a new pharmacy subsidiary aimed at diversifying revenue streams and rebuilding market confidence.

Healius Limited has announced a special fully franked dividend of AUD 0.413 per ordinary share, signaling confidence in its financial position despite the ongoing suspension of its Dividend Reinvestment Plan.

Healius Limited has announced a fully franked special dividend of 41.3 cents per share totaling approximately $300 million, alongside a new $300 million three-year syndicated bank facility replacing its previous $680 million arrangement.

Proteomics International Laboratories Ltd is raising up to $5.5 million through a $4 million placement and a $1 million Share Purchase Plan at $0.37 per share, offering shareholders a discounted entry and free attaching options.

Neurotech International has reported excellent safety and tolerability for its lead drug NTI164 in 28-day GLP toxicology studies, paving the way for regulatory submissions and longer-term clinical development.

4DMedical has landed a significant commercial contract with Intermountain Health to deploy its FDA-cleared Pulmonary Hypertension Analysis (PHA™) product, marking a key milestone in its U.S. expansion through a strategic Microsoft-backed partnership.

Alterity Therapeutics has secured FDA Fast Track designation for ATH434, its lead candidate for treating Multiple System Atrophy, potentially speeding up regulatory review and bringing hope to patients with this rare neurodegenerative disorder.

Next Science Limited has successfully had a derivative complaint dismissed in Florida, while continuing legal action against former employees for breach of post-employment restraints.

Immutep’s combination of eftilagimod alfa (efti) and KEYTRUDA® delivers a striking 17.6-month median overall survival in head and neck cancer patients with low PD-L1 expression, a group with limited treatment options.

MedAdvisor Limited’s trading suspension has been lifted immediately following the release of an announcement about the outcome of a court application under the Corporations Act 2001.

Opyl Limited has successfully raised $1.5 million through an oversubscribed placement to accelerate the growth of its AI-driven clinical trial platform, Trialkey. The capital injection underscores strong investor confidence as the company prepares for a pivotal expansion phase.